LOG IN
SIGN UP
MARKET
REGN
REGN
Regeneron Pharmaceuticals
NASDAQ
Real-time Quotes | Nasdaq Last Sale
687.27
+3.83
+0.56%
Opening 10:30 05/27 EDT
OPEN
685.72
PREV CLOSE
683.44
HIGH
687.27
LOW
680.00
VOLUME
116.58K
TURNOVER
68.44M
52 WEEK HIGH
747.42
52 WEEK LOW
492.13
MARKET CAP
75.49B
P/E (TTM)
9.74
1D
5D
1M
3M
1Y
5Y
SpringWorks (SWTX) Down Despite Desmoid Tumors Study Meeting Goal
SpringWorks' (SWTX) phase III study evaluating its investigational candidate, nirogacestat, in adult patients with progressing desmoid tumors, meets primary and key secondary endpoints.
Zacks · 1d ago
Biotech Stock Roundup: ETTX Up on Acquisition Deal, REGN Offers Updates
Regulatory updates and acquisition news from Entasis (ETTX) and Regeneron (REGN) are a few key highlights from the biotech sector during the past week.
Zacks · 2d ago
Sanofi, Regeneron's Dupixent Gets FDA Nod for 4th Indication (Revised)
The FDA approves Sanofi's (SNY) Dupixent for treating adults and children aged 12 and older with eosinophilic esophagitis, a chronic, progressive inflammatory disease.
Zacks · 2d ago
Regeneron Brings in the Big Money
Regeneron Pharmaceuticals, Inc. (REGN) stock has jumped, rising 34.6% over the past year.
FX Empire · 3d ago
Regeneron's (REGN) Evkeeza Positive in Late-Stage Study
Regeneron (REGN) announces positive data on a phase III study on cholesterol treatment Evkeeza.
Zacks · 3d ago
Regeneron initiated at outperform at Leerink on strength of Dupixent, Eylea, and pipeline
Leerink has initiated Regeneron Pharmaceuticals (NASDAQ:REGN) with an outperform rating citing the company's strong sales of Dupixent (dupilumab) and Eylea (aflibercept). The firm has a $738 price target (~12% upside
Seekingalpha · 4d ago
Benzinga's Top Ratings Upgrades, Downgrades For May 23, 2022
Benzinga · 4d ago
Sanofi, Regeneron's Dupixent Gets FDA Nod for 4th Indication
The FDA approves Sanofi's (SNY) Dupixent for treating adults and children aged 12 and older with eosinophilic esophagitis, a chronic, progressive inflammatory disease.
Zacks · 4d ago
No Data
Learn about the latest financial forecast of REGN. Analyze the recent business situations of Regeneron Pharmaceuticals through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating
Based on 24 analysts
Buy
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
20.83%Strong Buy
33.33%Buy
41.67%Hold
4.17%Under-perform
0.00%Sell
Analyst Price Target
The average REGN stock price target is 701.48 with a high estimate of 790.00 and a low estimate of 565.00.
Current 687.22
EPS
Actual
Estimate
6.9913.9820.9827.97
Institutional Holdings
Institutions: 1.41K
Institutional Holdings: 98.40M
% Owned: 89.58%
Shares Outstanding: 109.85M
TypeInstitutionsShares
Increased
365
7.15M
New
127
461.51K
Decreased
386
4.60M
Sold Out
106
251.86K
- Performance
- Asset Allocation
- Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.05%
Pharmaceuticals & Medical Research
+0.47%
Key Executives
Chairman/Director
P. Roy Vagelos
President/Chief Executive Officer/Founder/Director
Leonard Schleifer
Co-President/Chief Scientific Officer/Director
George Yancopoulos
Chief Financial Officer/Executive Vice President - Finance
Robert Landry
Executive Vice President/General Counsel/Secretary
Joseph LaRosa
Executive Vice President/General Manager
Daniel Van Plew
Executive Vice President
Marion McCourt
Executive Vice President
Andrew Murphy
Executive Vice President
Neil Stahl
Senior Vice President/Controller
Christopher Fenimore
Independent Director
Bonnie Bassler
Independent Director
Michael Brown
Independent Director
N. Anthony Coles
Independent Director
Joseph Goldstein
Independent Director
Christine Poon
Independent Director
Arthur Ryan
Independent Director
George Sing
Independent Director
Marc Tessier-Lavigne
Independent Director
Huda Zoghbi
No Data
No Data
About REGN
Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious diseases. The Company's commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases, and rare diseases. It is also engaged in the research, development of monoclonal antibodies, which consists of Dupixent, Kevzara, and itepekimab. The Company's marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, Kevzara (sarilumab) Solution for Subcutaneous Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion.
Webull offers kinds of Regeneron Pharmaceuticals Inc stock information, including NASDAQ:REGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, REGN stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading REGN stock methods without spending real money on the virtual paper trading platform.